Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Prevalence and clinical characteristics of patients with brain metastases at diagnosis with advanced hepatocellular carcinoma in a retrospective registry. Concurrent transarterial chemoembolization ...

Concurrent transarterial chemoembolization plus atezolizumab and bevacizumab in unresectable hepatocellular carcinoma: Interim analysis from a multicenter real-world study (CHANCE 023). This is an ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.

Purpose: The α-FAtE score, composed of alpha-fetoprotein, alkaline phosphatase, and eosinophil levels, has been reported as a predictor of prognosis in hepatocellular carcinoma (HCC) patients treated ...

Last accessed: April 2023. vi Hack SP, Spahn J, Chen M et al. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab ...

Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.